chain priorities and discuss our goals. three issues financial strategic over and against as I'll fourth then shareholders our results. the of for provide of I'll supply address call, progress of call I to detail our to you ongoing our Thanks, urgent us XXXX XXXX. the and all thank highlights hand further current top result execution industry as Brett financial joining results overview year high-level On our we quarter on to Amy, of well our today ResMed's opportunities. towards and for will review our June a quarter, fiscal today's as actions strategic review
questions Let me last start with month and the situation stakeholder that half. generated in the many has
Sleep ability quarter, industry's same During freight of constraints impacting teams products. and on earnings chain Executive are announcement, the for Care and as chain. to confirmed unprecedented and challenging recent our their a limitations ongoing for automotive, they product costs have Global putting well dramatically after Respiratory competitors including demand supply demand issues. consumer are electronic components, for increase devices recall additional environment pressure respond supply ResMed's our in calls an our already surged the as to technology that with the across industries on struggling communications ResMed shortage
have components major producers suggested chip XX months. shortages or could even the and electronic XX Some extend
our We need components the supply our further production chain we are working of supply global increase incredibly that closely ensure additional critical partners of devices. to medical access with to to
In During real high very to been we capacity have guiding chain forced this constraints. to supply these June and world our due the demand quarter, simple. products unprecedented that demand spike the doing are was principles allocate so, so
the needs allocation the patient to very first. highest ventilator It's our focused are We acuity approach peaks these on crisis to during months. XX the similar last COVID of
peaks our frustrating open of stakeholders customer after the understand as and up situation continue and all our coordinate begin for we a ultimate of with most industry, supply situation We importantly all It a equipment is including in the to this our customer, develops, time flow patient. unique COVID-XX the will steady patient physicians, with countries. various groups, providers, home We payers, medical to recovery constraints. is in the of
help be competitor other simultaneously. patients, that through those priority clear recall, to with treatment it our constraints diseases. who chain I With want need these always sleep and an disease best apnea, all supply pulmonary chronic obstructive be and unforeseen to respiratory will occurring all doing for our global
that when the to get that they need patients and ensure they is need goal Our therapy it.
not our respiratory two almost by leading Let They we situation remains a me to We're the things. our the one best and be increase the of very are player in X clear position Positive been created to apnea. caused compete Airway this Pressure And safe and scale. XXX that two, sleep further comfortable care just up apnea to the need number therapies. competitor components connected number the the to that One, most the can ResMed past, fill in worldwide. pieces market. we gold the our in doing sleep supply and that at the were all the And to gap use. has partner to further market supply supply the to treatment the order and the entire are chain therapy manufacture that devices couple standard a about the in smallest, for of They the of able of everything ago. They ResMed by access will we are be weeks most quietest, countries
somewhat throughout fiscal We XXXX. expect June market the chain news constrained released to on to only year XX. This be competitor was environment supply in from a our
first the of weeks So we our are in X.X response.
external. of chain We and be And the expansion will current December global already partnered both for supply supply see we the internal supply quarter do with although ahead. quarter XXXX expect room the However, have and most we team our constrained.
March of the that the ResMed quarters. expect will XXXX and during products June We accelerate significantly flow the XXXX
to on accelerated our XXXX million XXXX. analysis, in and planned million chain over diagnosed the and growth revenue model for previously investors while get the financial future We above supply growth are with and important, to our latest newly our in we this Based $XXX financials. most analysts our impact that additional ResMed of providers path and on upon see distributors devices impact a revenue fiscal is our focused I partnering information And $XXX physicians, human that know to ensure need to patients. our fiscal to
clear integrated solutions. see sustainable long-term to patients, Importantly, leading our as market opportunity and software a physicians experience our providers cloud-based increase device we ResMed market share, and
we adherence And over inferior AirSense doing distant brand want be and don't our since XX% the that XX. X we of the can labor last years back to providers platform up Solutions solutions, over near own yes, online called Air patient plus over own scale drive the digital lower rates to they an our suite their when our experience launch full beyond. that, by to platform product future, After starting health costs Our called solution. embrace XX%. adopt go they is their will of and next-generation new at can launched during They
overall me industry. turn conditions our to market Let in now
terms As sleep we in peak apnea flow. various stages COPD patient are the of and quarter, last discussed countries post-COVID process operate in the recovery we of at
in continued XX% even XXX% of seeing rolling patient to variants some in country. levels pre-COVID Vaccines levels including time of total pre-COVID in country flow the at cause disruption steadily countries. flow XX% the that countries same are We in the geographies. new are world out country-by-country. patient But And improvement Delta in to other or from by is around variance there wide some a variant continue
need provide committed remains with care the working for they hospitals Our acute training to that to ventilators, providers care. health masks and team and
home. that therapists really team operate countries throughout in. in in during its continue become things that adoption that world will has: well the investments frontline is ResMedian this are growth. health; and providers, we respiratory These and hygiene increased our support the physicians XXX two, three, and few A solutions; increased for have the focus its one, as pandemic and every to health and plus catalysts its We country clear outside increased hospital, treatment ResMed's as of health patients respiratory digital the respiratory in all on particularly long-term care
with progress new that COPD in seeing the and pleased are asthma steady We are we apnea, patients. sleep diagnosing
core end delivered the fourth growth with the quarter, was at quarter. sales headwind strong This apnea related respiratory the very XXXX the business. growth in of care our team June from right incredible million competitors our quarter, recall double-digit the tailwinds sleep and our ventilator of from During incremental some COVID lapping despite revenue $XXX sales and across
While and and annual revenue, over the battling year and with while X% profit over for total their flow to for XXXX in also of patient countries. leverage quarter, our constant billion performance I the the over all of ResMedians of fighting throughout $X.X XXX I'm growth producing recovery am Quite operating team in from X,XXX year revenue our fiscal achievement over a in helping people proud XX% team impacts. XX% non-GAAP growth COVID-XX growth this in in fiscal currency the with revenue proud very
therapy We respiratory improvement expect as to see and apnea flow fiscal patient we for year sleep in care move throughout our steady XXXX.
for home-based ongoing management. for patients, digital and see to health for adopting monitoring tools remote screening, and are population We providers patient encouraged for patient health physicians testing,
for other health As treatment the health drive digital COPD as and conditions, this are well-positioned chronic the respiratory to partners. apnea, care we of asthma our growth leader with delivery sleep as in well
we over we shareholders for in Today, cash share. return increase in XX announced dividend dividends to the to last shareholders cash per million During X% $XX $X.XX generated allowing us million of $XXX quarter, operating flow, our days. to these an quarterly
you, to cash flow. and business We your resilient our shareholders, ongoing to pleased in our our ResMed's return reflecting cash are confidence
All for in software for the masks, digital well increased and as costs operating device SG&A while maintaining line. the also for research. other as global development investments in our We R&D health quarter, fiscal and during and technology with devices, discipline clinical our research for embedded keeping
million lead market. for population the long-term over XX health the devices field engagement cloud management We patient remote We connectable medical with are and in growth. reinvesting of
right health position leading provide take will providers physicians are keep and granted, we to their patients, for we Our partner every and to every and with market their innovation interaction. support. increasing our they digital value their it earn choice. every us, service product, ensure day Customers we wallets. earning plan don't to customer to We of have investments and to with in now share every solution, be And every vote for that to superior voting
business. are technologies digital for Our catalyst a growth health our
innovative cloud-based that an industry X,XXX Solutions. medium billion in over including leading value. called We X portfolio, platform over of pipeline our respiratory intellectual exciting Air an of long-term now have and generate have both solutions designs. patents will With property medical We and data nights
support the comes our we opportunity ecosystem. with called engagement is physicians. platform upgraded in serverless over supports the tool patient our enrolled We This release means cloud-based we full for to that platform AirView cloud is with The our what with And XX called AirSense capabilities new XX. for myAir delivery, This have next-generation and recently our with all and for myAir. now cycle the new in have that innovation data AirSense native million software cloud. architecture, scalable market app X.X And patients accelerated teams. XX.X solution in improved
We million for patients, XXX for have Software-as-a-Service to providers, of incredible data for care. well as physicians, of as all community hospital serve. for that communities for within private -- our allow patients out groups, These value over assets government our managed and they and payers the us network for unlock customer
These accelerated you priorities. research well deliver especially best as we differentiate AirSense COPD and software to AirSense and grow world's industry world-leading called our businesses; the core Let medical in previewed delivered three, launch current strategic our team me health care digital situation, design, globally; and platform and outside hospital, asthma leading Responding to the are: three now solutions scaled grow be one, quarter, to and gen the XX. on development that as Last solutions develop to home. of next apnea, update innovate XX. top the our the sleep and the market and for two, can our devices
over countries time. launches ResMed. launch last overlap device launch the AirSense will launch the States device selling Previously new month. then platform expanding an minimize to this moving before by platforms. to a end This product in control to this history of to We and additional quarter, in And launch product United launch be by like the gradually we expect device customers no to other timed date. earlier current of First, the full of the now product XX other carefully second just
today. a unique situation are in We
meet customers leading market. that be it is very better XX AirSense Our overall makes on time, short, XX AirSense our is given the to we quite the AirSense receive both right market devices now. in the ResMed IPAP this to bottom for and new XX sell to continues going be in market of strongly we markets as bilevel the it maximize adopted, The AirSense fiscal sense available that than demand for and ResMed the the line XX the for market help some the to we year. around Skype, parallel particularly at CPAP, volume over continue selling we're new and world. extraordinary sale unprecedented will this to to expand AirSense any and as other availability And In believe currently continue for demand XX geographies new device as to the the patients coming
excited control bring very physicians, AirSense XX when to product positive. launch very partners the and device I bed are to been and combination to our response and am understating say overall care AirSense systems. the I platform will benefits results the We also market, and software XX that health and the patients payers benefit providers, has
connectable inherence All I are health cloud and our technology XX on health comfortable the customers the also most before smartest and make market. the the clever cost digital never are patients reductions most and deliver and outcomes devices. improve engaging As to devices own the we smallest, increase digital the connected to with XXX% said therapy and earlier, care quietest own they But the like engagement directly clinical in AirSense their in upgraded devices within patient proven the systems, to industry. most
turn business, now million disease of me chronic million patients to better the serve to our focusing strategy our worldwide. on XXX XXX respiratory pulmonary the Let asthma a obstructive care and patients discussion
offerings. sold hundreds drug high goal and areas connected Respiratory potential life Care with as therapeutic therapy and of many flow non-invasive as Our well newer ventilation, our as to Solutions, such to millions We reach respiratory business solutions, our of care support is pharmaceutical solutions June these cloud delivery including million time the ventilation, patients tune benefited ventilation as this and in to mass an last scale of COVID, for growing sales. we the acute XXXX year quarter the $XXX incremental that devices announced meet in demand on
had overall $XX They modest XXXX we our not ventilator material in results, sales. were were the they During current sales, under. quarter, June to under million COVID-related just
markets serve be in variant will global revenue resulting governments acute and our support surges and coronavirus the this there from to various still But do to in business. expect Delta As material systems they of we not COVID care to health the be patients regions, we and their the need.
humanitarian through impact in broader the countries. with course, life top measurable solutions, Of ventilation is priority of our of all these a preservation
then core, new help then ensure non-invasive that Lumis experiencing Stellar, Our support business. ventilation flow our and supply chain is support platforms same our focus and our for ventilation support non-invasive ventilator, for Demand life and sleep need for our AirCurve solutions Astral, in most. our the patient who we life to ventilator, COPD the can are patients our steady apnea and see recovery as we
that with last We the patient growth XX balance are it as supply of months chronic to made and with acute the demand inventory ventilators their the market throughout ongoing in customers balancing needs. ventilation
launched of that the Europe ventilation we We continue in solution adoption time to see rapid AirView this a year-ago. software for
being tool provided an also crisis, world. to helping we helpful clinical physicians not that the ongoing now care health it The standard only COVID increasingly value care to to technology the health is through respiratory during the but for that ventilation In has they systems digital operate for regions been and are the as is AirView expanding summary, around new ensure We in. of are for valuable care. this them for
of out health hospital Software-as-a-Service for Let now review our me business care.
health and across home During our continued SaaS home infusion, communities. hospice, care equipment, resupply COVID-XX business optimize The providing to improve for nursing growth in in care, challenging duty digits our to as customers care. is nursing some mid been facilities, And skilled portfolio plan the they private has including products. HME home skilled particularly of grow patient grew and medical with and SNFs. we single solutions utilize The life our quarter, our home tailwinds business, verticals our health, pandemic markets, continue for SaaS or year-over-year of home home-based facilities,
SNFs, and census settings. as improve seeing rates care we trends positive are across However, other
very this closely case varying the around rates of the watching peaks COVID are in We country. as
pipeline software restrictions for COVID there to We increase opportunities pent-up us as ease our be continue for to expect to provides purchasing demand our that state-by-state.
us position customers leading HME help software to choice provider maintain as the a of through Our to to enabled manage and business. healthy market the pandemic the
Our the within home current work the HMEs to software the support, as Brightree industry, ongoing allowing of needed increased need as medical well through for need shortages challenges branded equipment. much product including resupply are solutions patient our of for in management categories, some in growth
we single-digit solutions, portfolio high our of year. single-digit look fiscal end back across our gradually mid growth increasing SaaS current As revenue we to this its accelerate by growth from growth of expect the to
or As market as meet we always, to share growth beat from to continue our rates innovate take goal and these market is competitors.
screen growth. opportunities drive our on existing growth augment acquisitions see we Additionally, organic through SaaS our to to radar further
due value is We And of their good our that well can of provider each of offerings owner offering, In diligence, in of for to with increasing patients and have serve. for acute additional and in all history additional And course we minimize own verticals clients a course, ensuring in residents, ResMed the and we network. of for received from to of place, SaaS that ultimately, thorough a the leverage And bring shareholders. our best new that see analytics are our care people the hospital age allow value homes. away customers to the we an to our summary, opportunity preferably episodes asset. in
as across at our of confident ResMed's solutions, both SaaS products strategy our very and well Looking sleep we care solutions. of long-term innovative pipeline in businesses respiratory and remain the our portfolio and as
drives and ever has lives than COVID importance is day. million digital awareness on through and The as better the brighter monitoring be it shining respiratory accelerated highlighted motivates XXX pandemic. specific remote can was patient of health hygiene Our and screening, goal technologies set in improve used as diagnosis up adoption health importance the also XXXX this to health, every well light of of mission ResMedians for and that due and to care it's patient management.
to sleep engagement solutions suffering We continue and see and enrollment, remain billion ResMed the COPD our ensure long-term digital and a to ecosystem. R&D for With within people provide X.X incredible asthma, opportunities growth. invest in we from aggressively for world identification, around people over leading health catalyst greater of apnea, market
provide expand we to in. that countries development and to technology all innovation across driving this operate the relentlessly are the impact XXX of needed scale of We the
Before to his I want almost my hand more X,XXX for their during call sincere perfect over hard and the again dedication express than circumstances. I for the work Brett remarks, the gratitude unusual, to ResMedians storm of to most perseverance,
You many customers to we lives helped now world through the support last have save ventilation over our of chain of we the with have company suffered Sydney go pivoted around dynamics Brett With during Q&A thousands months whole provide XX rapidly over the needs unprecedented of these in emergency that, to back for people and will as and then COVID. Brett, the and call ongoing for hundreds constraints demand. you patients with industry And challenging to supply hand you. I'll to team. very the with Thank you.
